By Laura Schanberg, MD
Over 400 CARRA members, research associates, parents, patients, Arthritis Foundation leaders, representatives from the Lupus Foundation of America, Cure JM, and NIAMS, and pharma colleagues attended the CARRA Annual Meeting in Toronto, April 14-17. It was the most well-attended CARRA meeting to date! The meeting program received highly positive evaluations from attendees. Our thanks go out to the planning committee, including Stacy Ardoin, Suzanne Li, Peter Blier, and Kelly Mieszkalski, for their hard work.
WHAT CAUGHT OUR EYE
By Jay Mehta, MD
“What about dietary changes?” I’m sure I’m not alone in getting this question more and more frequently with each passing year. It’s interesting that as our drugs get more effective at treating patients, families seem to be more interested in trying to treat with non-pharmacologic means.
With 1,230 subjects enrolled in the CARRA Registry at 50 sites, we are on track to enroll approximately 3300 by the end of the year. We have posted two articles with enrollment tips, https://carragroup.org/chop-tips/ and https://carragroup.org/profile-seattle-childrens-hospital/), and we will continue to profile successful sites and learn from their experiences.
The Childhood Arthritis and Rheumatology Research Alliance (CARRA), Inc. announced today that the first two patients had enrolled in the Start Time Optimization in Polyarticular Juvenile Idiopathic Arthritis (STOP-JIA) project. STOP-JIA aims to answer a critical question facing patients and doctors: “When is the best time to start biologic medications in polyarticular JIA?”
Nominations due 6/1 for Small Centers Vice Chair
The Elections Committee is seeking nominations for the CARRA Small Centers Vice Chair. Nominees must be current voting members from a CARRA small center (3 or fewer pediatric rheumatologists).
Nominations are due June 1st. Nominee application materials are due June 8th.
Click here to review the position responsibilities along with information about the nomination and application processes. Self-nominations are accepted and the 5% salary support is provided for this position.
CARRA is part of a new national research network called PARTNERS, which links researchers, patient communities, clinicians, and health care systems.
STOP–JIA (Start Time Optimization in Polyarticular Juvenile Idiopathic Arthritis) is a prospective, observational study comparing the clinical effectiveness and impact on patient reported outcomes of 3 different treatment strategies (CTPs) in new onset pJIA patients to answer the critical question of when to start biologic medications.
View the STOP-JIA Prezi.